In 2026, AI is evolving from an auxiliary tool to a core driving force in the field of healthcare. The medical imaging AI diagnostic system has been implemented in more than 3000 hospitals worldwide. In the detection tasks of pulmonary nodules, breast cancer, retinopathy, etc., the diagnostic accuracy of AI has exceeded the average level of senior radiologists. The AI imaging diagnostic platform independently developed by China has completed over 200 million auxiliary screenings, covering more than 15000 primary healthcare institutions.
In the field of drug development, generative AI is completely changing the paradigm of new drug discovery. Companies represented by Insilico Medicine and Recursion Pharmaceuticals have achieved full process automation using AI, from target discovery to candidate molecule optimization. In the first half of 2026, the world's first new drug designed entirely by AI and entering phase III clinical trials demonstrated better safety and efficacy data than traditional methods, marking the transition of AI pharmaceuticals from concept validation to commercialization.
What is even more exciting is the progress of personalized treatment. AI models based on multi omics data (genome, proteome, metabolome) can customize precise treatment plans for each patient. In the field of tumor treatment, AI driven digital twin technology can simulate the efficacy of different drug combinations on patients' tumors in a virtual environment, helping doctors choose the optimal treatment plan and reducing trial and error time from months to days.
From wearable devices to remote monitoring, AI is building a continuous health management loop from hospitals to homes. It is expected that by 2027, the global AI healthcare market will exceed $200 billion, and AI+healthcare integration is redefining the boundaries of human health management.